THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

This announcement is not a solicitation of consent with respect to any Series 002 Notes (as defined below). The Consent Solicitation (as defined below) is being made solely pursuant to the Consent Solicitation Statement (as defined below) and related documents which set forth the complete terms of the Consent Solicitation.

This announcement and any materials relating to the Consent Solicitation do not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law.

The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about, and to observe, any such restrictions.

COMMENCEMENT OF CONSENT SOLICITATION EXERCISE BY THOMSON MEDICAL GROUP LIMITED (THE "ISSUER") IN CONNECTION WITH ITS S$175,000,000 4.05 PER CENT. NOTES DUE 2025 (ISIN: SGXF89249654) COMPRISED IN SERIES 002 (THE "SERIES 002 NOTES") ISSUED BY THE ISSUER PURSUANT TO THE S$500,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME OF THE ISSUER (THE "PROGRAMME").

Shareholders of the Issuer who are not otherwise holders of the Series 002 Notes will not be eligible to attend or vote at the Meeting of the Series 002 Notes either in person or by proxy.

Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the consent solicitation statement dated 28 March 2023 (the "**Consent Solicitation Statement**") issued by the Issuer.

The Issuer wishes to announce that it has today commenced a consent solicitation process to seek the approval of the holders of the Series 002 Notes (the "**Noteholders**") by way of an Extraordinary Resolution of the Noteholders to, *inter alia*, (a) amend the ratio of Consolidated Net Debt to Consolidated Total Equity set out in the financial covenant under Clause 8.2.2 of the Trust Deed and Condition 4(b)(ii) of the Series 002 Notes; and (b) amend the notice provisions under Condition 16 of the Series 002 Notes such that notices to the holders of such Series 002 Notes shall also be valid if published on the website of the SGX-ST at http://www.sgx.com (the changes and amendments contemplated above, the "**Amendments**") (the "**Consent Solicitation**").

Noteholders should carefully consider all of the information, in particular the risk factors, set forth in the Consent Solicitation Statement.

DBS Bank Ltd. has been appointed as solicitation agent in connection with the Consent Solicitation.

For further details on the Consent Solicitation, Noteholders are advised to refer to the notice of meeting published in *The Business Times* on 28 March 2023 and the Consent Solicitation Statement.

A copy of the Consent Solicitation Statement will be mailed to the Direct Participants with an address in Singapore. In order to avoid any violation of laws applicable in countries other than Singapore, the Consent Solicitation Statement has not been and will not be mailed to Direct Participants who do not presently have an address in Singapore ("**Foreign Noteholders**"). Foreign Noteholders who wish to obtain a copy of the Consent Solicitation Statement should provide in writing such address in Singapore

to Tricor Singapore Pte. Ltd. (trading as Tricor Barbinder Share Registration Services), as meeting agent, in connection with the Consent Solicitation (the "**Meeting Agent**"), not later than five (5) business days before the Expiration Time (as defined below).

In addition, Noteholders may collect copies of the Consent Solicitation Statement, the Voting Certificate and the Voting Instruction Form from the office of the Meeting Agent, at 80 Robinson Road #11-02 Singapore 068898, between 9.00 a.m. to 5.00 p.m. (Singapore time) from Mondays to Fridays (excluding public holidays), up to 10.00 a.m. (Singapore time) on 17 April 2023 or 48 hours before any adjourned Meeting (the "**Expiration Time**"). Noteholders are required to make an appointment with the Meeting Agent prior to any collection.

The latest time and date for Noteholders to submit a duly completed Voting Instruction Form to the Meeting Agent (containing Voting Instructions to have their votes cast in favour of the Extraordinary Resolution at the Meeting) to be eligible for the Early Consent Fee (subject to the fulfilment and/or waiver of the Settlement Conditions and provided such Voting Instructions have not been validly revoked) is 5.00 p.m. (Singapore time) on 10 April 2023, or such later time and date as the Issuer may determine (the "**Early Consent Fee Deadline**").

Subject to the fulfilment and/or waiver of the Settlement Conditions, Noteholders who vote in favour of the Extraordinary Resolution at the Meeting or deliver, or arrange to have delivered on their behalf, valid Voting Instructions after the Early Consent Fee Deadline but on or prior to the Expiration Time to the Meeting Agent to have their votes cast in favour of the Extraordinary Resolution at the Meeting (and such Voting Instructions have not been validly revoked) will not be eligible for the Early Consent Fee but will instead be eligible to receive a Normal Consent Fee.

Questions and requests for further information and assistance in relation to the Consent Solicitation or the Consent Solicitation Statement or in connection with the submission or delivery of Voting Instructions and/or Voting Instruction Forms may be directed to the Meeting Agent between 9.00 a.m. to 5.00 p.m. (Singapore time) from Mondays to Fridays (excluding public holidays).

BY ORDER OF THE BOARD
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group Chief Executive Officer
28 March 2023